PlexusDx sourced semaglutide from licensed 503A compounding pharmacies follows evidence-based protocols to help patients achieve consistent, safe weight loss results
Symptom journaling lets users keep track of side effects in detail to share with healthcare providers
Consult with a medical expert before using the patch
While highly effective for glycemic control and weight reduction, gastrointestinal adverse effects are commonly reported, with constipation rates varying by indication and dosageapproximately 3-9% in diabetes treatment (Ozempic, Rybelsus) and up to 24% in weight management (Wegovy)
Currently, a phase 3 clinical trial program for retatrutide (TRIUMPH) is underway to assess its safety and efficacy in different obese patient populations, including those with obstructive sleep apnea (OSA), T2D, diagnosed cardiovascular disease, osteoarthritis, and others
Side effect monitoring: The gastrointestinal side effects of Wegovy (nausea, constipation) are usually manageable but should be reported to your prescriber